Physicians' Academy for Cardiovascular Education

Heart Failure

Recently added learning

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD

Patient profiling in HFrEF to tailor therapy

5' education - June 21, 2001 - Pardeep Jhund, MD, PhD

No definite difference for primary endpoint but proven safety with ARNI in MI patients

5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Treatment algorithms for HFpEF

10' education - May 4, 2021 - Prof. John Cleland, MD

Recommendations for treatment algorithm of HFrEF

10' education - Apr. 26, 2021 - Andrew Coats, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD - Online CME

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD - Online CME

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD - Online CME

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD - Online CME

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD - Online CME

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada

ARNI as first-line therapy in de novo HFrEF patients after ADHF event

3' education - June 3, 2019

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands - Online CME

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)
##FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##FULL_TITLE##

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##FULL_TITLE##

Heart failure news at the ESC

10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

10' education - June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

Two additions to the therapeutic armory to treat HFrEF

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA

Managing cardiorenal syndrome in the context of heart failure

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA
##FULL_TITLE##

New 2016 ESC Heart Failure Guidelines

3' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors (Groningen, The Netherlands)
##FULL_TITLE##

The spectrum of Heart Failure

10' education - May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##FULL_TITLE##

Review of cardiovascular safety of DPP4 inhibitors

3' education - May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##FULL_TITLE##

No benefit of direct renin inhibition in HF in ATMOSPHERE trial

3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Lars Køber
##FULL_TITLE##

HF Summit : innovation in clinical care in heart failure

10' education - Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##FULL_TITLE##

A multidisciplinary approach in heart failure management

10' education - Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet
##FULL_TITLE##

Living with heart failure: A patient perspective

3' education - Oct. 30, 2015 - HF Summit, Barcelona, Spain - Nick Hartshorne-Evans
##FULL_TITLE##

Diagnosing Heart Failure: How, where and who?

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Prof. Burkert Pieske
##FULL_TITLE##

Novel insights and innovations in targeting the neurohumoral system

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer
##FULL_TITLE##

A global overview of key developments in Heart Failure: Where are we now?

3' education - Oct. 30, 2015 - HF Summit, Barcelona, Spain - Dr. Kenneth Dickstein
##FULL_TITLE##

How to classify your HF patients? Understanding HFpEF versus HFrEF

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Carolyn Lam
##FULL_TITLE##

The advent of novel nonsteroidal mineralocorticoid receptor antagonists in heart failure

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof Bertram Pitt
##FULL_TITLE##

Major new phase in heart failure management

3' education - Nov. 9, 2015 - AHA 2015, Orlando, FL, USA - Milton Packer
##FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##FULL_TITLE##

PARADIGM-HF: Rationale, results & implications

3' education - Dec. 11, 2014 - Chicago, Il, USA VBWG - John J McMurray
##FULL_TITLE##

Innovating hypertension: targeting the underlying disease process

3' education - Sep. 8, 2014 - Barcelona - Prof Bryan Williams
##FULL_TITLE##

Innovating hypertension management beyond current therapies: What are the opportunities?

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom
##FULL_TITLE##

Emerging therapies in acute heart failure

3' education - Apr. 27, 2013 - VBWG at ACC - Dr. John R. Teerlink
##FULL_TITLE##

Effects of GLP-1 Analogs on Cardiovascular Health

3' education - Jan. 10, 2013 - LA, AHA 2012 - Dr. Richard Shannon
##FULL_TITLE##

Update: Heart Failure and Mineralocorticoid Receptor

3' education - Jan. 5, 2013

On demand 10" video

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Treatment algorithms for HFpEF

10' education - May 4, 2021 - Prof. John Cleland, MD

Recommendations for treatment algorithm of HFrEF

10' education - Apr. 26, 2021 - Andrew Coats, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD - Online CME

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD - Online CME

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD - Online CME

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD - Online CME

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands - Online CME

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris
##FULL_TITLE##

Heart failure news at the ESC

10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

10' education - June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands
##FULL_TITLE##

The spectrum of Heart Failure

10' education - May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##FULL_TITLE##

HF Summit : innovation in clinical care in heart failure

10' education - Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##FULL_TITLE##

A multidisciplinary approach in heart failure management

10' education - Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet
##FULL_TITLE##

Innovating hypertension management beyond current therapies: What are the opportunities?

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD
Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.

Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.

Patient profiling in HFrEF to tailor therapy

5' education - June 21, 2001 - Pardeep Jhund, MD, PhD
Guidelines need to be translated to treatment of individual patients. For support in the decision-making, a recent article was published on identifying patient profiles in HFrEF to tailor therapies.

Guidelines need to be translated to treatment of individual patients. For support in the decision-making, a recent article was published on identifying patient profiles in HFrEF to tailor therapies.

No definite difference for primary endpoint but proven safety with ARNI in MI patients

5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD
A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.

ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD
Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.

Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.

Treatment algorithms for HFpEF

10' education - May 4, 2021 - Prof. John Cleland, MD
Prof. Cleland guides us through data from clinical trials that investigated pharmacological treatments in HF and discusses a treatment algorithm for HFpEF.

Prof. Cleland guides us through data from clinical trials that investigated pharmacological treatments in HF and discusses a treatment algorithm for HFpEF.

Recommendations for treatment algorithm of HFrEF

10' education - Apr. 26, 2021 - Andrew Coats, MD
Many patients with HFrEF are currently not at target dose of recommended pharmacological treatments for HFrEF. A revised algorithm is needed to get patients at target doses more quickly.

Many patients with HFrEF are currently not at target dose of recommended pharmacological treatments for HFrEF. A revised algorithm is needed to get patients at target doses more quickly.

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD
Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD
The 2021 update to the 2017 heart failure ECDP was just published. Prof. Januzzi explains the contribution of this document in addition to the guidelines and shares the most important updates.

The 2021 update to the 2017 heart failure ECDP was just published. Prof. Januzzi explains the contribution of this document in addition to the guidelines and shares the most important updates.

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD
In the AFFIRM-AHF trial, the effect of administration of IV ferric carboxymaltose at hospital discharge on hard outcomes was examined in patients stabilized after an acute HF episode and concomitant iron deficiency.

In the AFFIRM-AHF trial, the effect of administration of IV ferric carboxymaltose at hospital discharge on hard outcomes was examined in patients stabilized after an acute HF episode and concomitant iron deficiency.

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD
Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD
Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD
Prof. Van der Meer gives an introduction to the symposium about comorbidities in HF with a specific focus on hyperkalemia, that was held during the virtual ESC 2020 congress.

Prof. Van der Meer gives an introduction to the symposium about comorbidities in HF with a specific focus on hyperkalemia, that was held during the virtual ESC 2020 congress.

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD - Online CME
RAAS inhibitors can cause hyperkalemia in HF patients. Javed Butler explains how novel potassium binders may improve management of patients with chronic HF by continuation of RAASi.

RAAS inhibitors can cause hyperkalemia in HF patients leading to RAASi downtitration or discontinuation. Novel potassium binders may improve management of HF patients by continuation of RAASi.

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD - Online CME
Prof. Ponikowski discusses the importance of optimization of RAASi treatment through long-term potassium control in HF patients.

Prof. Ponikowski discusses the importance of optimization of RAASi treatment through long-term potassium control in HF patients with hyperkalemia.

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD - Online CME
Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.

Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD
Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.

Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME
Two cardiologists, one in an ambulatory setting and one in a hospital setting, discuss the treatment of a patient with severe heart failure following an MI over the course of two years.

Two cardiologists, one in an ambulatory setting and one in a hospital setting, discuss the treatment of a patient with severe heart failure following an MI over the course of two years.

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD
Niels Grote Beverborg talks about multiple aspects of iron deficiency without anemia in HF, including outcomes, mechanisms, diagnosis, etiology and treatment options.

Niels Grote Beverborg talks about multiple aspects of iron deficiency without anemia in HF, including outcomes, mechanisms, diagnosis, etiology and treatment options.

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD
Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effects of SGLT2 inhibitors.

ESC 2020 Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effect of SGLT2 inhibitors.

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD
Which characteristics increase clinical suspicion for amyloidosis, and how should ATTR-cardiomyopathy, a type of amyloidosis, be diagnosed and treated?

Which characteristics increase clinical suspicion for amyloidosis, and how should ATTR-cardiomyopathy, a type of amyloidosis, be diagnosed and treated?

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD
Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray
Prof. McMurray discusses briefly the outcomes of the EMPEROR-Reduced trial, evaluating the effect of empagliflozin in HFrEF patients, and compares the results to those of the DAPA-HF trial.

ESC 2020 Prof. McMurray discusses briefly the outcomes of the EMPEROR-Reduced trial, evaluating the effect of empagliflozin in HFrEF patients, and compares the results to those of the DAPA-HF trial.

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD
Two dilemmas in use of sacubitril/valsartan for heart failure patients are discussed in this presentation: Should sacubitril/valsartan be used in HFpEF patients and as initial treatment in HFrEF patients?

Two dilemmas in use of sacubitril/valsartan for heart failure patients are discussed in this presentation: Should sacubitril/valsartan be used in HFpEF patients and as initial treatment in HFrEF patients?

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD
The co-chairs introduce the topic of this symposium by explaining that many novel therapies for HFrEF have resulted in difficulties in decision-making for management of these patients. The presentations in this series may help in decision-making in a personalized, case-based approach.

The co-chairs introduce the topic of this symposium by explaining that many novel therapies for HFrEF have resulted in difficulties in decision-making for management of these patients. The presentations in this series may help in decision-making in a personalized, case-based approach.

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD - Online CME
Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.

Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD - Online CME

Using a case of a heart failure (HF) patient who was admitted to the hospital with acute decompensated HF (ADHF), two specialists discuss what the optimal treatment strategy in hospitalized patients should be during time of admission.

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD
Jonathan Cunningham discusses three findings from subanalyses of the PARAGON-HF trial in HFpEF patients.

ACC 2020 Jonathan Cunningham shares three major findings from a subanalysis of the PARAGON-HF trial in HFpEF patients.

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020
The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon
Prof. Solomon gives a comprehensive overview of the PARAGON-HF trial and presents results of an analysis of combined data of the PARADIGM-HF and PARAGON-HF trials.

Prof. Solomon gives a comprehensive overview of the PARAGON-HF trial and presents results of an analysis of combined data of the PARADIGM-HF and PARAGON-HF trials. With question to test your knowledge.

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD
The EVALUATE-HF trial was set up to study the effects of sacubitril/valsartan treatment on cardiac and hemodynamic mechanisms, to look into how these may explain the observed clinical benefits.

The EVALUATE-HF trial was set up to study the effects of sacubitril/valsartan treatment on cardiac and hemodynamic mechanisms, to look into how these may explain the observed clinical benefits.

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD
Prof. Pieske gives a broad overview of heart failure with mid range ejection fraction, including prevalence, etiolgies and treatment options.

Prof. Pieske gives a broad overview of heart failure with mid range ejection fraction, including prevalence, etiolgies and treatment options.

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD
A subanalysis of the PIONEER-HF trial was performed to examine whether sacubitril/valsartan was effective and safe in high-risk subgroups. Prof Morrow gives a brief presentation of this analysis.

A subanalysis of the PIONEER-HF trial was performed to examine whether sacubitril/valsartan was effective and safe in high-risk subgroups. Prof Morrow gives a brief presentation of this analysis.

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD
Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.

Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia
As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI.

AHA 2019 As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia
A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.

AHA 2019 A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia
Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.

AHA 2019 Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD
Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.

CSI Paris Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD
Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.

ESC 2019 Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.

Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD
Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD
As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD
SGLT2 inhibitors reduce CV endpoints most likely through a reduction of HF-related events. Prof. Marx discusses potential underlying mechanisms explaining the beneficial effects of this drug class on HF.

SGLT2 inhibitors reduce CV endpoints most likely through a reduction of HF-related events. Prof. Marx discusses mechanisms potentially explaining the beneficial effects of this drug class on HF.

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD
Prof. Dirk Jan van Veldhuisen shares results of the PARAGON-HF trial, showing non-significant reductions in CV mortality and hospitalization for HF with sacubitril/valsartan vs. valsartan in HFpEF patients, and discusses subgroup analyses.

ESC 2019 Prof. Dirk Jan van Veldhuisen shares results of the PARAGON-HF trial, showing non-significant reductions in CV mortality and hospitalization for HF with sacubitril/valsartan vs. valsartan in HFpEF patients, and discusses subgroup analyses.

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller
A strategy of early and sustained vasodilation in acute HF patients was unable to reduce all-cause death and rehospitalization for acute HF.

ESC 2019 A strategy of early and sustained vasodilation in acute HF patients was unable to reduce all-cause death and rehospitalization for acute HF.

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray
DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon
Sacubitril/valsartan was tested in HFpEF patients in the PARAGON-HF trial. The reduction in HF hospitalizations and CV death just missed significance, but heterogeneity was seen for the treatment effect.

ESC 2019 Sacubitril/valsartan was tested in HFpEF patients in the PARAGON-HF trial. The reduction in HF hospitalizations and CV death just missed significance, but heterogeneity was seen for the treatment effect.

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp
Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.

ESC HF 2019 Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens
TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.

ESC HF 2019 TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD - Online CME
Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.

Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten
Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.

ESC HF 2019 Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD
During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.

During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD
Based on a case description, prof. van der Meer explains how to diagnose HFpEF based on amyloidosis. Futhermore, he talks about current and future treatments options for patients with transthyretin amyloid cardiomyopathy.

Based on a case description, prof. van der Meer explains how to diagnose HFpEF based on amyloidosis. Futhermore, he talks about current and future treatments options for patients with transthyretin amyloid cardiomyopathy.

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.

Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.

Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD
Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK
What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.

What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada
Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.

Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.

ARNI as first-line therapy in de novo HFrEF patients after ADHF event

3' education - June 3, 2019
Michele Senni gives a short presentation of a subanalysis of the TRANSITION trial, comparing the rate of patients on sacubitril/valsartan after 10 weeks in de novo vs. previously diagnosed HFrEF patients.

ESC HF 2019 Michele Senni gives a short presentation of a subanalysis of the TRANSITION trial, comparing the rate of patients on sacubitril/valsartan after 10 weeks in de novo vs. previously diagnosed HFrEF patients.

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019
Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.

ESC HF 2019 Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019
Previous results have shown benefits in mortality and HF hospitalization with MitraClip. New data complement the previous findings and demonstrate improved quality of life with MitraClip in HF patients with secondary MR.

ACC 2019 Previous results have shown benefits in mortality and HF hospitalization with MitraClip. New data complement the previous findings and demonstrate improved quality of life with MitraClip in HF patients with secondary MR.

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019
In the MOMENTUM 3 trial, the centrifugal-flow pump HeartMate 3 was compared with the axial-flow pump HeartMate 2 in patients with advanced HF. Prof. Uriel discusses the findings and implications of this trial.

ACC 2019 In the MOMENTUM 3 trial, the centrifugal-flow pump HeartMate 3 was compared with the axial-flow pump HeartMate 2 in patients with advanced HF. Prof. Uriel discusses the findings and implications of this trial.

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019
Pulmonary artery pressure-guided therapy in class III HF patients met the primary efficacy and two safety endpoints at 1 year in the CardioMEMS trial.

ACC 2019 Pulmonary artery pressure-guided therapy in class III HF patients met the primary efficacy and two safety endpoints at 1 year in the CardioMEMS trial.

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD
Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.

ACC 2019 Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD
Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits.

Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD
Prof. Montanya DMdiscusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trials, respectively.

Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.

HFpEF: Current and future clinical approaches to manage HFpEF

HFpEF: The essentials to know

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME
Prof. Burkert Pieske summarizes current treatment strategies for HFpEF and discusses new treatment options that are currently being investigated.

HFpEF: The essentials to know Prof. Burkert Pieske summarizes current treatment strategies for HFpEF and discusses new treatment options that are currently being investigated.

Practice-changing results on in-hospital treatment of acute decompensated HF

AHA 2018 - Chicago, IL, USA

3' education - Nov. 15, 2018 - Larry Allen, MD
Based on the PIONEER-HF results, Larry Allen will now confidently start guideline-recommended therapy in-hospital, for patients with acutely decompensated heart failure.

AHA 2018 Based on the PIONEER-HF results, Larry Allen will now confidently start guideline-recommended therapy in-hospital, for patients with acutely decompensated heart failure.

Initiation of ARNI in patients with acute decompensated heart failure

AHA 2018 - Chicago, IL, USA

3' education - Nov. 13, 2018 - Eric Velazquez, MD
Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

AHA 2018 – Chicago, IL, USA

3' education - Nov. 12, 2018 - Jane Wilcox, MD
The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.

AHA 2018 The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.

HFpEF: How to diagnose

HFpEF: The essentials to know

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME
There are several diagnostic approaches for HFpEF. Dr. Borlaug discusses their usefulness and limitations.

HFpEF: The essentials to know There are several diagnostic approaches for HFpEF. Dr. Borlaug discusses their usefulness and limitations.

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

HFpEF: The essentials to know

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME
Prof. Carolyn Lam presents six mechanisms that may underlie the pathophysiology of HFpEF. She discusses why these mechanisms may be targeted for therapy.

HFpEF: The essentials to know Prof. Carolyn Lam presents six mechanisms that may underlie the pathophysiology of HFpEF. She discusses why these mechanisms may be targeted for therapy.

HFpEF: What is it & size of the problem

HFpEF: The essentials to know

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands - Online CME
Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF

HFpEF: The essentials to know Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands
Prof. Van der Meer describes the prevalence of hyperkalemia and its effects on the use of RAAS inhibition and discusses some potential novel potassium binders.

Prof. Van der Meer describes the prevalence of hyperkalemia and its effects on the use of RAAS inhibition and discusses some potential novel potassium binders.

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy
In a randomized trial treatment with tafamidis resulted in impressive, significantly reduced mortality and hospitalization due to CV events in patients with ATTR-CM and HF.

ESC 2018 In a randomized trial treatment with tafamidis resulted in impressive, significant reduced mortality and hospitality due to CV events in patients with ATTR-CM and HF.

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME
Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.

Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME
Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME
Dr. Kotecha explains how the pathophysiologies of HFpEF and atrial fibrillation are interconnected, and what this means for management of patients with both conditions.

Dr. Kotecha explains how the pathophysiologies of HFpEF and atrial fibrillation are interconnected, and what this means for management of patients with both conditions.

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA
**ACC 2018** The MOMENTUM 3 study results show a large reduction in stroke and need for reoperation, as no pump thrombosis occurred, with the new Heartmate 3 device, in comparison with the Heartmate 2.

ACC 2018 The MOMENTUM 3 study results show a large reduction in stroke and need for reoperation, as no pump thrombosis occurred, with the new Heartmate 3 device, in comparison with the Heartmate 2.

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore
Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.

Professor Lam lists five mechanisms in which she recognizes targets for treatment of patients with heart failure with preserved ejection fraction. These mechanisms are currently tested as therapeutic strategies.

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA
Kyla Lara presented a poster at the AHA on her research on the effect of various dietary patterns, based on Food Frequency Questionnaires, on the risk of developing heart failure.

AHA 2017 Kyla Lara presented a poster at the AHA on her research on the effect of various dietary patterns, based on Food Frequency Questionnaires, on the risk of developing heart failure.

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME
PACE-CME symposium held at ESC 2017 - Heart failure & Diabetes: Time for a more unified approach

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris
The HeartLogic system combines several parameters including heart sound, respiratory rate and patient activity, into an algorithm that can identify patients at risk of developing HF decompensation. Prof. Cowie discusses how this advances the field and what remains to be done.

ESC HF 2017 The HeartLogic system combines parameters including heart sound, respiratory rate and patient activity, to identify HF patients at risk of developing decompensation. Prof. Cowie discusses what remains to be done to advance the field.

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris
At the ESC HF congress in Paris, professor Voors shares the disappointing results of the RELAX-AHF, in which treatment with serelaxin in acute HF did not result in improvement in mortality and worsening HF

ESC HF 2017 At the ESC HF congress in Paris, professor Voors shares the disappointing results of the RELAX-AHF, in which treatment with serelaxin in acute HF did not result in improvement in mortality and worsening HF

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris
Prof. Martin Cowie discusses the relationship between diabetes and renal dysfunction and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.

Diabetes and renal dysfunction are very common in patients with heart failure. Prof. Martin Cowie discusses the relationship and the cardiovascular effect of new therapeutic classes to control diabetes in high-risk patients.

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris
Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

Diabetes and diabetic kidney disease are associated with increased risk of cardiovascular disease and remarkably shortened life expectancy. Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris
Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.

Heart failure is the most disabling and deadly complication of diabetes. Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)
Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist.

Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)
Dr. Mathew Maurer, MD, explains that TTR amyloid is an unrecognized and potentially modifiable cause of HFpEF

Dr. Mathew Maurer, MD, explains that TTR amyloid is an unrecognized and potentially modifiable cause of HFpEF and other age related cardiac conditions. He describes novel imaging techniques and treatments for this condition.

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##KEY_PHRASE##

AHA 2016 Dirk jan van Veldhuisen shares the data of the EFFECT- HF study, in which HF patients who received ferric carboxymaltose had stable peak VO2 after 6 months of follow-up, while deterioration was seen in the control group.

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##KEY_PHRASE##

Iron deficiency impairs quality of life and exercise capacity in heart failure patients. The new ESC HF guidelines recommend measuring and treating iron deficiency to help these patients.

Extra work of checking device data weekly does not translate into benefit for HF patient

ESC - 2016 Rome

3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##KEY_PHRASE##

Martin Cowie shares the very clear results of the REM-HF study addressing the question whether outcome can be improved in patients with heart failure with an implanted device, if device data are collected remotely on a weekly basis.

Heart failure news at the ESC

ESC - 2016 Rome

10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##KEY_PHRASE##

ESC 2016 Prof. dr. Frank Ruschitzka was chairperson in the heart failure Hot Line session at the ESC 2016. He considers the implications of the mostly neutral results observed in the presented trials on ICD, telemonitoring and stem cell therapy.

Heart Failure news from ESC 2016 at a glance

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)
##KEY_PHRASE##

ESC 2016 Prof. Mariell Jessup (Philadelphia, PA, USA) chaired the ESC Hot Line sesion on Heart Failure. She summarises the findings of remote monitoring studies and stem cell trial and touches upon the discussion this raised. 

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome
Heart Failure & Diabetes: SGLT2 inhibition a paradigm shift?

John McMurray, MD, describes how SGLT2 inhibitors may work in preventing heart failure in diabetes.

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

10' education - June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

ESC HF 2016 Kenneth Dickstein considers the increase in potassium levels that arise as a consequence of blocking the renin-angiotensin system. Hyperkalemia is often a reason for not following guideline-recommended therapy, which underlines the need for novel potassium-lowering therapy.

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

ESC HF 2016 The results of the EMPA-REG outcome trial have changed views on how SGLT2 inhibition may yield benefit. Naveed Sattar describes the emerging mechanistic concept based on the latest trial data.

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

ESC HF 2016 Conventional therapies to treat hyperkalemia are associated with clinical complications. Peter van der Meer discusses the mechanism and efficacy and safety results of two new therapeutic options that lower potassium levels: patiromer and ZS-9.

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

ESC HF 2016 Many HF patients are treated suboptimally, with hyperkalemia being one of the underlying reasons. Faiez Zannad considers this clinical scenario, its consequences and how it can be managed.

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

ESC HF 2016 David Fitchett discusses the results of the EMPA-REG OUTCOME trial: the first published trial evaluating CV endpoints with an SGLT2 inhibitor.

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

ESC HF 2016 Patients with both HF and diabetes have poor prognosis. Adriaan Voors reviews which currently available therapies provide benefit and which may increase risk in these patients.

Two additions to the therapeutic armory to treat HFrEF

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA
Two new pharmacologic therapies for use in patients with HFrEF that have been FDA-approved: the heart-rate reducing agent ivabradine and sacubitril/valsartan, a combination of an ARB and a neprilysin inhibitor.

Scott Solomon describes the two new pharmacologic therapies for use in patients with HFrEF that have been approved by the FDA in the past year: the heart-rate reducing agent ivabradine and sacubitril/valsartan, a combination of an ARB and a neprilysin inhibitor.

Managing cardiorenal syndrome in the context of heart failure

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA
in 25% of patients with acute decompensated HF, a cardiorenal syndrome can develop, in which serum creatinine rises and kidney injury may develop. Pharmacotherapeutic options are discussed.

McCullough addresses the concept of a cardiorenal syndrome, specifically in the context of heart failure. in 25% of patients with acute decompensated HF, serum creatinine rises and kidney injury may develop. He considers the effects of various pharmacotherapeutic options.

New 2016 ESC Heart Failure Guidelines

3' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors (Groningen, The Netherlands)
##KEY_PHRASE##

ESC HF 2016 Adriaan Voors, ESC Heart Failure Guideline Task Force Co-Chairman summarises the most important changes in the 2016 guideline presented in Florence at the ESC Heart Failure Congress today, as compared with the 2012 guidelines.

The spectrum of Heart Failure

10' education - May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##KEY_PHRASE##

Dr. Marc Pfeffer (Boston, MA, USA) considers what therapy may benefit patients across the whole spectrum of HF, and acknowledges that clearly effective therapy is still missing for HFpEF, but new options might appear at the horizon.

Review of cardiovascular safety of DPP4 inhibitors

3' education - May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##KEY_PHRASE##

Dr Rajagopalan, MD, Maryland, USA reviews the utility of DPP4 inhibitors in T2DM patients with high CVD risk.

No benefit of direct renin inhibition in HF in ATMOSPHERE trial

3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Lars Køber
##KEY_PHRASE##

ACC 2016 Lars Køber (Copenhagen, Denmark) discusses that direct renin inhibition with aliskiren did not improve the primary outcome as compared with enalapril, in patients with heart failure, in the ATMOSPHERE trial. Interpretation of the study results was hampered by the removal of diabetic patients during the trial, based on results in other studies.

HF Summit : innovation in clinical care in heart failure

10' education - Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##KEY_PHRASE##

HF Summit The chairmen of the HF summit look back at a successful meeting and recapitulate what they learnt from the interaction with the audience and where most attention is needed to improve HF care.

A multidisciplinary approach in heart failure management

10' education - Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet
##KEY_PHRASE##

HF Summit Different professionals involved in HF care exchange ideas about optimal multidisciplinary care of HF patients could be organised, from the perspective of a nurse, a general practitioner and a cardiologist.

Living with heart failure: A patient perspective

3' education - Oct. 30, 2015 - HF Summit, Barcelona, Spain - Nick Hartshorne-Evans
##KEY_PHRASE##

HF Summit Mr. Hartshorne-Evans is a heart failure patient and he runs a patient-driven HF charity in the UK. He shares patient perspectives on the use of the word 'heart failure' and he considers how disease awareness may be improved.

Diagnosing Heart Failure: How, where and who?

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Prof. Burkert Pieske
##KEY_PHRASE##

HF Summit 2015 Prof. Pieske gives an overview of how to diagnose both HFrEF and HFpEF.

Novel insights and innovations in targeting the neurohumoral system

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer
##KEY_PHRASE##

HF Summit 2015 - Dr. Van der Meer (Groningen, The Netherlands) summarises currently available drugs to treat HFrEF and the evidence for their efficacy.

A global overview of key developments in Heart Failure: Where are we now?

3' education - Oct. 30, 2015 - HF Summit, Barcelona, Spain - Dr. Kenneth Dickstein
##KEY_PHRASE##

HF Summit Dr. Kenneth Dickstein considers what are the most effective interventions in heart failure management, thereby acknowledging that certain existing management options could be applied better.

How to classify your HF patients? Understanding HFpEF versus HFrEF

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Carolyn Lam
##KEY_PHRASE##

HF Summit 2015 Dr. Lam explains the differences between HFpEF and HFrEF and how this translates into (new) therapies.

The advent of novel nonsteroidal mineralocorticoid receptor antagonists in heart failure

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof Bertram Pitt
##KEY_PHRASE##

AHA 2015 Prof Bertram Pitt summarises current evidence and upcoming trials of mineralocorticoid receptor antagonists in general, and of the novel non-steroidal MRA finerenone in particular.

Major new phase in heart failure management

AHA 2015, Orlando, FL, USA

3' education - Nov. 9, 2015 - AHA 2015, Orlando, FL, USA - Milton Packer
##KEY_PHRASE##

AHA 2015 Prof. Milton Packer describes the clinical implications of the new dual inhibitor of the renin-angiotensin system and neprilysin. 

PARAMETER: heart failure agent to treat hypertension

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##KEY_PHRASE##

ESC 2015 The PARAMETER study evaluated LCZ696, the agent that was found to be effective against heart failure in the PARADIGM-HF, in another population of patients with systolic hypertension. Prof. Bryan Williams discusses the results.

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##KEY_PHRASE##

ESC 2015 The PARAMETER study evaluated LCZ696, the agent that was found to be effective against heart failure in the PARADIGM-HF, in another population of patients with systolic hypertension.

PARADIGM-HF: Rationale, results & implications

3' education - Dec. 11, 2014 - Chicago, Il, USA VBWG - John J McMurray
##KEY_PHRASE##

Prof John McMurray, Glasgow, explains the backgrounds of this trial with a novel ARNI and its potental implications for future Heart Failure management

Innovating hypertension: targeting the underlying disease process

3' education - Sep. 8, 2014 - Barcelona - Prof Bryan Williams
##KEY_PHRASE##

Prof. Bryan Williams (London) urges the need for innovation to control systolic BP in our aging population

Innovating hypertension management beyond current therapies: What are the opportunities?

Prof Bryan Williams, London, United Kingdom

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom
##KEY_PHRASE##

Lecture held by Prof Bryan Williams, MD, UCL, London, United Kingdom on 'Innovating hypertension management beyond current therapies: What are the opportunities?' held during the PACE 2014 Snapshot session in Barcelona

Emerging therapies in acute heart failure

3' education - Apr. 27, 2013 - VBWG at ACC - Dr. John R. Teerlink
##KEY_PHRASE##

Dr John Teerlink highlights recent trials in the management of acute heart failure and outlines some emerging new developments

Effects of GLP-1 Analogs on Cardiovascular Health

3' education - Jan. 10, 2013 - LA, AHA 2012 - Dr. Richard Shannon
##KEY_PHRASE##

Dr. Richard Shannon, Pennsylvania,  recognizes that Diabetes is a CVD equivalent and focuses on the importance that incretins can play in improving hemodynamics and outcomes in Heart Failure.

Update: Heart Failure and Mineralocorticoid Receptor

3' education - Jan. 5, 2013
##KEY_PHRASE##

Prof Bertram Pitt, Michigan provides a brief update on Heart Failure with current evidence with MRAs ..